title: Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
abstract: OBJECTIVE
  Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin. However, it is not known whether the protection against the devastating tissue injuries extends into extravasation with new types of anthracyclines, the anthracenediones, or the liposomal pegylated anthracycline formulations. We therefore tested the antidotal efficacy of dexrazoxane against extravasation of amrubicin, mitoxantrone, and liposomal pegylated doxorubicin in mice.
  
  
  METHODS
  A total of 80 female B6D2F1 mice were tested in an established mouse extravasation model. The mice had experimental extravasations of amrubicin, mitoxtanrone, and Caelyx and were immediately hereafter treated with systemic dexrazoxane or saline.
  
  
  CONCLUSIONS
  Systemic treatment with dexrazoxane resulted in significant protection against extravasation injuries from all three drugs. Moreover, the vesicant potential of the three test drugs was weaker than seen in previous experiments with the classic anthracyclines.
authors.affiliation: Department of Oncology 5073, The Finsen Center, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark. seppo.langer@rh.regionh.dk
authors.forename: Seppo W
authors.initials: SW
authors.lastname: Langer
authors.forename: Annemette V
authors.initials: AV
authors.lastname: Thougaard
authors.forename: Maxwell
authors.initials: M
authors.lastname: Sehested
authors.forename: Peter Buhl
authors.initials: PB
authors.lastname: Jensen
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000633:toxicity*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D051379:Mice; D008942:Mitoxantrone / Q000633:toxicity*; D011929:Razoxane / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D011929:Razoxane; D004317:Doxorubicin; C055866:amrubicin; D008942:Mitoxantrone